Professor Nadia Di Muzio is a Head of the Radiotherapy Department in the San Raffaele Research Hospital in Milan since 2008. She has a degree in general medicine and surgery and specialty in oncological radiotherapy from the University of Milan and has done an internship at the Department of Radiation Oncology in the University of Madison. Professor Di Muzio is an author of 200 studies in radiation oncology research and an advocate of high-precision hypofraction methods in the radical treatment of prostate tumors. She currently holds positions in the Italian Association of Medical Oncology, the Italian Society of Oncological Urology and the European Society for Radiotherapy and Oncology.
Read moreProfessor Nadia Di Muzio is a Head of the Radiotherapy Department in the San Raffaele Research Hospital in Milan since 2008. She has a degree in general medicine and surgery and specialty in oncological radiotherapy from the University of Milan and has done an internship at the Department of Radiation Oncology in the University of Madison. Professor Di Muzio is an author of 200 studies in radiation oncology research and an advocate of high-precision hypofraction methods in the radical treatment of prostate tumors. She currently holds positions in the Italian Association of Medical Oncology, the Italian Society of Oncological Urology and the European Society for Radiotherapy and Oncology.
Associate Professor of Thoracic Surgery with European Board qualifications. Head of mini-invasive thoracic surgery unit, specializing in the treatment of lung and pleural diseases and mediastinal disorders. Member of Italian Society of Thoracic Surgery and Thoracic Endoscopy, as well as author of a monograph and over 200 scientific publications.
Read moreAssociate Professor of Thoracic Surgery with European Board qualifications. Head of mini-invasive thoracic surgery unit, specializing in the treatment of lung and pleural diseases and mediastinal disorders. Member of Italian Society of Thoracic Surgery and Thoracic Endoscopy, as well as author of a monograph and over 200 scientific publications.
Professor Santoro is heavily involved in research, with interest in many topics, such as the development of new cancer drugs and new biological therapies, interests for solid and haematological tumours, and not only he treats cancer survivors but also patients with comorbidities.
He has worked in Humanitas Research Hospital for 22 years. Professor Santoro’s post-graduate research was carried out at the Unité de Development Therapeutique (Institut de Cancerologie et d’Immunogenetique, Villejuif of Paris) from 1974 to 1975, and in the Division of Medical Oncology of the National Cancer Institute of Milan from 1976 to 1977.
In 1977, he specialized in Clinical and Laboratory Haematology at University of Rome. In 1979, he completed his fellowship post-graduate work in the Memorial Sloan Kettering Cancer Center of New York and later, at Stanford University. In 1980, he specialized in oncology at the University of Genoa.
Current Teaching Activity: Professor Santoro worked as Contract Professor at the Specialization School in Clinical Pathology ad Pavia University from 1992 to 1997. Also, from 1993 to 2002 he has been President of the Rare Tumour Group. Now he is full professor at Humanitas University.
Current Positions:
In addition, Professor Santoro’s unique expertise was recognized through numerous awards, such as the Managing Doctor of the Year award (2013), the City of Siena S. Caterina d’Oro Award (2013, Serra Association Award for scientific research) and social and healthcare commitment (Salerno, 2009).
Publications: santoro%a - Search Results - PubMed (nih.gov)
Read moreProfessor Santoro is heavily involved in research, with interest in many topics, such as the development of new cancer drugs and new biological therapies, interests for solid and haematological tumours, and not only he treats cancer survivors but also patients with comorbidities.
He has worked in Humanitas Research Hospital for 22 years. Professor Santoro’s post-graduate research was carried out at the Unité de Development Therapeutique (Institut de Cancerologie et d’Immunogenetique, Villejuif of Paris) from 1974 to 1975, and in the Division of Medical Oncology of the National Cancer Institute of Milan from 1976 to 1977.
In 1977, he specialized in Clinical and Laboratory Haematology at University of Rome. In 1979, he completed his fellowship post-graduate work in the Memorial Sloan Kettering Cancer Center of New York and later, at Stanford University. In 1980, he specialized in oncology at the University of Genoa.
Current Teaching Activity: Professor Santoro worked as Contract Professor at the Specialization School in Clinical Pathology ad Pavia University from 1992 to 1997. Also, from 1993 to 2002 he has been President of the Rare Tumour Group. Now he is full professor at Humanitas University.
Current Positions:
In addition, Professor Santoro’s unique expertise was recognized through numerous awards, such as the Managing Doctor of the Year award (2013), the City of Siena S. Caterina d’Oro Award (2013, Serra Association Award for scientific research) and social and healthcare commitment (Salerno, 2009).
Publications: santoro%a - Search Results - PubMed (nih.gov)
Filippo de Marinis is the Director of the Thoracic Oncology Unit at the European Centre for Oncology (Milan, Italy). The doctor leads clinical trials of new methods in the treatment of malignant tumors of the chest organs.
The doctor's experience is more than 30 years.
In 1978, De Marinis completed his studies in Pulmonology at the Sapienza University of Rome. From 1983 to 1986, he specialized in oncology at the Catholic University of the Sacred Heart in Rome. Filippo De Marinis then worked as a physician at the Carlo Forlanini Hospital and the Institute for Clinical Trials and Pneumophysiological Research. Since 2007, he has taught pulmonology at the Campus Biomedico private university in Rome and at the Sapienza University of Rome. Since 2013, the professor has been head of the Thoracic Cancer Unit at the European Oncology Center.
An appointment with Filippo de Marinis lasts from 40 to 60 minutes. During this time, the doctor collects the patient's medical history and compares it with the examination results. In order to establish an accurate diagnosis or plan an operation, the doctor will prescribe additional tests if necessary.
Professor de Marinis is the author of 250 scientific publications in 130 medical journals. As one of the leading experts in the treatment of lung cancer, he has spoken at 300 scientific congresses over the past 5 years.
The doctor participates in national and international clinical trials of new drugs.
Filippo de Marinis is the Director of the Thoracic Oncology Unit at the European Centre for Oncology (Milan, Italy). The doctor leads clinical trials of new methods in the treatment of malignant tumors of the chest organs.
The doctor's experience is more than 30 years.
In 1978, De Marinis completed his studies in Pulmonology at the Sapienza University of Rome. From 1983 to 1986, he specialized in oncology at the Catholic University of the Sacred Heart in Rome. Filippo De Marinis then worked as a physician at the Carlo Forlanini Hospital and the Institute for Clinical Trials and Pneumophysiological Research. Since 2007, he has taught pulmonology at the Campus Biomedico private university in Rome and at the Sapienza University of Rome. Since 2013, the professor has been head of the Thoracic Cancer Unit at the European Oncology Center.
An appointment with Filippo de Marinis lasts from 40 to 60 minutes. During this time, the doctor collects the patient's medical history and compares it with the examination results. In order to establish an accurate diagnosis or plan an operation, the doctor will prescribe additional tests if necessary.
Professor de Marinis is the author of 250 scientific publications in 130 medical journals. As one of the leading experts in the treatment of lung cancer, he has spoken at 300 scientific congresses over the past 5 years.
The doctor participates in national and international clinical trials of new drugs.